Gilead Posts 3Q EPS of $1.94
GILD sits 44% above its 52-week low of $114.02.
Summary
Gilead reported third-quarter adjusted EPS of $2.55 and revenue of $8.3B, with net income of $2.43B. Sales excluding Veklury rose 16%. The company boosted full-year product sales guidance to $31B, up from $30.1B to $30.4B, and raised its FY26 base revenue guidance. Its FY26 diluted loss per share guidance widened to $4.40-$4.05 GAAP and $1.20-$0.85 non-GAAP, reflecting ~$9.88 per share from $12.4B in acquired IPR&D charges. Context matters here: Q2 revenue of $7.8B beat the $7.4B consensus by 5.4% and management raised full-year guidance. The stock sits near its 52-week high of $165.70, so expectations are elevated.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Gilead's FY26 diluted loss per share guidance widened to $4.40-$4.05 GAAP and $1.20-$0.85 non-GAAP, reflecting ~$9.88 per share from $12.4B in acquired IPR&D charges.
At the time of this announcement, GILD was trading at $164.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $205.3B. The 52-week trading range was $114.02 to $165.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.